Non-Randomized, Open-Label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Heparin (Primary)
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Therapeutic Use
- Acronyms ISAR-REACT-3A
- 05 Jan 2012 Biomarkers information updated
- 04 Jan 2012 Actual patient number is 2505 according to ClinicalTrials.gov.
- 04 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.